MO-I-1100 

MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. MO-I-1100 suppresses HCC cell migration, invasion and anchorage independent growth. MO-I-1100 shows antitumor effects through inhibiting Notch signaling cascade in HCC^[1].

MO-I-1100 has no effect on viability of NIH3T3 cells which lacked ASPH on the cell surface^[1].
MO-I-1100 (1-10 μM) inhibits the viability of FOCUS cells, which have high level ASPH expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MO-I-100 (50 mg/kg, ip, for 5 consecutive days per week for 2 weeks and then administered every other day) reduces tumor growth in an intrahepatic orthotopic xenograft model of HCC^[1].
MO-I-1100 (50 mg/kg/day, ip, for 5 days) reduces the activated Notch 1 (cleaved fragment) as well as downstream HES1 and HEY1 gene expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

379.81

C₁₇H₁₄ClNO₅S

1585217-40-8

O=C1C(OS(CC2=CC=CC=C2)(=O)=O)=C(N)OC1C3=CC=C(Cl)C=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Aihara A, et al. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014 Oct;60(4):1302-13.  [Content Brief]